RESEARCH · NAD+ · PRECURSORS
NAD+ Precursors Compared: What Human Trials of NR and NMN Actually Measure
Interest in raising nicotinamide adenine dinucleotide (NAD+) has shifted from cell biology into human supplementation trials — mostly with precursors, not with intact NAD+ itself. Our earlier article, NAD+: coenzyme biology, CD38 and PARP consumption, covered consumption pathways and delivery puzzles. This article compares what peer-reviewed human studies of nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) actually report, and why those results do not automatically transfer to a lyophilized NAD+ research vial. PurixLab’s NAD+ 500mg is supplied for laboratory research use only.
Why precursors dominate the clinical literature
NAD+ is a redox cofactor and a substrate for sirtuins, PARPs and other NAD+-consuming enzymes. Levels fall with stress and ageing in many experimental systems, which motivates replenishment strategies [1,2]. Orally studied precursors in humans are chiefly NR and NMN; systematic mapping of the literature found far more preclinical than clinical papers, and benefitrisk reviews still treat intact NAD+/NADH human data as thinner than precursor data [2,3]. A 2024 Nature Reviews article stresses unresolved compartmentation, microbiome handling of precursors, and non-canonical degradation routes — reasons blood NAD+ rises may not equal useful tissue NAD+ [1].
Nicotinamide riboside: bioavailability and chronic use
The first human pharmacokinetics work on NR reported that a single oral amount raised blood NAD+ as much as 2.7-fold in a pilot individual, and that single oral amounts of 100, 300 and 1000 mg produced graded increases in the blood NAD+ metabolome; nicotinic acid adenine dinucleotide (NAAD) emerged as a sensitive repletion biomarker [4].
An 8-week randomised, double-blind, placebo-controlled trial in overweight but otherwise healthy adults found that oral NR at 100, 300 and 1000 mg raised whole-blood NAD+ by 22%, 51% and 142% within 2 weeks, with increases maintained for the rest of the study and no significant adverse-event differences versus placebo [5]. A separate 2 × 6-week crossover trial in healthy middle-aged and older adults concluded that chronic NR was well tolerated and stimulated NAD+ metabolism, while flagging blood pressure and arterial stiffness as endpoints for larger trials [6].
Disease-oriented pilots are beginning to appear. In peripheral artery disease, a randomised trial reported that 6 months of NR improved 6-minute walk distance versus placebo (+7.0 versus −10.6 metres; between-group difference +17.6 m) [7]. These are selected populations and endpoints; they do not establish broad clinical indications.
Nicotinamide mononucleotide: smaller, more recent human sets
Single oral NMN amounts of 100, 250 and 500 mg in 10 healthy men did not produce significant clinical symptoms or meaningful vital-sign changes over a 5-hour observation window in a non-randomised safety study [8]. A 10-week randomised, placebo-controlled trial in postmenopausal women with prediabetes who were overweight or obese reported that NMN increased insulin-stimulated glucose disposal on clamp testing and increased skeletal-muscle insulin signalling (AKT and mTOR phosphorylation), without claiming weight-loss equivalence to other metabolic drugs [9].
A 28-day randomised study of microcrystalline β-NMN (MIB-626) in overweight or obese adults aged ≥45 years (randomised 2:1 active to placebo) found substantial rises in circulating NAD and metabolites, with greater reductions than placebo in body weight (−1.9 kg), diastolic blood pressure (−7.01 mmHg), total cholesterol (−26.89 mg/dL) and LDL cholesterol (−18.73 mg/dL) [10]. In recreational runners, a six-week four-arm trial (48 participants) reported training-plus-NMN effects on ventilatory-threshold power and related aerobic indices versus training plus placebo [11]. Sample sizes remain modest relative to cardiovascular outcome trials.
What about intact NAD+?
Most human NAD+-augmentation papers use NR or NMN, not oral or parenteral NAD+ as the investigational product [2,3]. Reviews emphasise that extracellular NAD+ handling, ectoenzyme cleavage and tissue distribution are poorly resolved, so a research vial of NAD+ is not interchangeable with a precursor capsule used in a trial [1]. Measurement itself is non-trivial: whole-blood NAD+, plasma metabolomes, tissue biopsies and imaging-based readouts answer different questions and are not always concordant [4,1].
Open questions for laboratory readers
- Blood ≠ target tissue. Large blood NAD+ rises (for example 142% at the highest NR amount in Conze et al.) do not prove equivalent rises in liver, muscle or brain [5,1].
- Precursor ≠ NAD+ vial. NR/NMN trial results should not be read as evidence about intact NAD+ research materials [2].
- Small trials. Many NMN studies enrol tens of participants and short durations [8,10,9].
- Hard outcomes. Walk-distance and clamp endpoints are intermediate; long-term disease outcomes remain largely untested [7,6].
NAD+ 500mg at PurixLab
NAD+ 500mg: a labelled lyophilized research vial with 500mg per vial, C$109 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/nad-500mg/.
PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.
In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.
Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.
For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.
Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ
References
- Migaud ME, Ziegler M, Baur JA. Regulation of and challenges in targeting NAD+ metabolism. Nat Rev Mol Cell Biol. 2024;25(10):822-840. PubMed 39026037 · PMC12456757 · doi:10.1038/s41580-024-00752-w
- Braidy N, Liu Y. NAD+ therapy in age-related degenerative disorders: A benefit/risk analysis. Exp Gerontol. 2020;132:110831. PubMed 31917996 · doi:10.1016/j.exger.2020.110831
- Alegre GFS, Pastore GM. NAD+ Precursors Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR): Potential Dietary Contribution to Health. Curr Nutr Rep. 2023;12(3):445-464. PubMed 37273100 · PMC10240123 · doi:10.1007/s13668-023-00475-y
- Trammell SA, Schmidt MS, Weidemann BJ, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 2016;7:12948. PubMed 27721479 · PMC5062546 · doi:10.1038/ncomms12948
- Conze D, Brenner C, Kruger CL. Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults. Sci Rep. 2019;9(1):9772. PubMed 31278280 · PMC6611812 · doi:10.1038/s41598-019-46120-z
- Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286. PubMed 29599478 · PMC5876407 · doi:10.1038/s41467-018-03421-7
- McDermott MM, Martens CR, Domanchuk KJ, et al. Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial. Nat Commun. 2024;15(1):5046. PubMed 38871717 · PMC11176364 · doi:10.1038/s41467-024-49092-5
- Irie J, Inagaki E, Fujita M, et al. Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocr J. 2020;67(2):153-160. PubMed 31685720 · doi:10.1507/endocrj.EJ19-0313
- Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. PubMed 33888596 · PMC8550608 · doi:10.1126/science.abe9985
- Pencina KM, Valderrabano R, Wipper B, et al. Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study. J Clin Endocrinol Metab. 2023;108(8):1968-1980. PubMed 36740954 · PMC11491622 · doi:10.1210/clinem/dgad027
- Liao B, Zhao Y, Wang D, et al. Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study. J Int Soc Sports Nutr. 2021;18(1):54. PubMed 34238308 · PMC8265078 · doi:10.1186/s12970-021-00442-4